Fractyl Health is developing innovative therapies to address the root cause of type 2 diabetes and obesity. Our groundbreaking research and biological insights showed the key role of the intestine in metabolic control. Our lead program, Revita, is designed to target and control the intestine for the treatment of metabolic disease. Revita is a first-in-class procedural therapy that is now in late-stage clinical trials for the treatment of type 2 diabetes. Our pipeline also includes Rejuva, a pancreatic gene therapy, which is in preclinical development for restoration of beta cell health in type 2 diabetes. Our team is made up of passionate innovators at the intersection of biology and technology, working to deliver better real-world outcomes for people with metabolic disease. Fractyl Health is located in Burlington, Mass.